New TRITON analysis shows further benefits for prasugrel
This article was originally published in Scrip
Executive Summary
A new analysis of data from the Phase III TRITON-TIMI 38 trial has shown that patients receivingDaiichi Sankyo/Lilly's platelet inhibitor prasugrel (Effient) who survived their first cardiovascular event were 35% less likely to suffer a similar recurrent event than those on clopidogrel (Sanofi-Aventis's Plavix/Iscover).